Daniel C. Martin - 17 Jan 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Chief Commercial Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jan 2023
Net transactions value
-$34,050
Form type
4
Filing time
19 Jan 2023, 15:05:45 UTC
Previous filing
21 Jun 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Sale $34,050 -1,603 -3.2% $21.24 48,389 17 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was to cover tax liabilities in the vesting of restricted stock.
F2 Includes 471 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2022.